Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Metis TechBio CoFRA:RO9 +7.99%17 EBITDA Margin % is -4,013.48% as of Dec. 2025. GuruFocus rates FRA:RO9 with a GF Score™ of 17/100. The stock has 1 warning sign investors should review. Among 942 Biotechnology companies, Metis TechBio Co ranks worse than 88.96% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Metis TechBio Co's EBITDA for the
three
months ended in Dec. 2025 was €-16.38 Mil. Metis TechBio Co's Revenue for the
three
months ended in Dec. 2025 was €0.41 Mil. Therefore, Metis TechBio Co's EBITDA margin for the quarter that ended in Dec. 2025 was -4,013.48%.
Metis TechBio Co (FRA:RO9) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Metis TechBio Co EBITDA Margin % Related Terms
Metis TechBio Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Metis TechBio Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metis TechBio Co EBITDA Margin % Chart
Metis TechBio Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
EBITDA Margin %
-90,900.00
-5,070.64
-19,628.35
-306.62
Metis TechBio Co Quarterly Data
Dec22
Dec23
Dec24
Sep25
Dec25
EBITDA Margin %
0.00
0.00
-15,732.76
0.00
-4,013.48
FRA:RO9 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Metis TechBio Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metis TechBio Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Metis TechBio Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Metis TechBio Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metis TechBio Co (FRA:RO9) has a EBITDA Margin % of -4,013.48% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Metis TechBio Co and its competitors. According to the industry distribution chart, Metis TechBio Co ranks #838 out of 942 companies in the Biotechnology industry, placing it in the top 89%.
Is Metis TechBio Co's EBITDA Margin % too high?
Metis TechBio Co's current EBITDA Margin % is -4,013.48%. Based on the distribution chart, Metis TechBio Co ranks #838 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Metis TechBio Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Metis TechBio Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Metis TechBio Co ranks #838 out of 942 companies for EBITDA Margin %. This places Metis TechBio Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Metis TechBio Co and its competitors. Metis TechBio Co's current EBITDA Margin % is -4,013.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metis TechBio Co stock overvalued right now?
Metis TechBio Co (FRA:RO9) has a current EBITDA Margin % of -4,013.48%. The current EBITDA Margin % is -4,013.48%. Metis TechBio Co's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Metis TechBio Co (FRA:RO9), the current EBITDA Margin % is -4,013.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Metis TechBio Co Ltd is an investment holding company. The company and its subsidiaries are principally engaged in AI-empowered nanomaterial innovation for the delivery and application of active agents across all carbon-based life forms. Its technology platform, NanoForge, comprises a set of integrated tools, including a lipid library, AI models, an AI agent (METiS), quantum chemistry and molecular dynamics simulations, and high-throughput screening platforms. The company has developed three solution platforms (AiTEM, AiLNP, and AiRNA) designed to simulate, predict, and interpret nanoscale interactions, enabling the rational design, optimization, and validation of nanomaterials and their associated payloads.
17GF Score
Get the complete analysis for FRA:RO9
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RO9 has been successfully added to your 
